YMC026 + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Respiratory Disease
Conditions
Respiratory Disease
Trial Timeline
Oct 27, 2017 → Oct 30, 2018
NCT ID
NCT03334916About YMC026 + Placebo
YMC026 + Placebo is a approved stage product being developed by Yuhan for Respiratory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03334916. Target conditions include Respiratory Disease.
What happened to similar drugs?
9 of 20 similar drugs in Respiratory Disease were approved
Approved (9) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03334916 | Approved | Completed |
Competing Products
20 competing products in Respiratory Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 35 |